PURPOSE: To investigate the in vitro binding properties of a novel radiolabelled bombesin analogue, (177)Lu-AMBA, in human neoplastic and non-neoplastic tissues selected for their expression of the bombesin receptor subtypes GRP-R, NMB-R and BRS-3. METHODS: In vitro receptor autoradiography was performed in cancers expressing the various bombesin receptor subtypes. The novel radioligand (177)Lu-AMBA was used and compared with established bombesin radioligands such as (125)I-Tyr(4)-bombesin and (125)I-[D-Tyr(6),beta-Ala(11),Phe(13),Nle(14)]-bombesin(6-14). In vitro incidence of detection of each of the three bombesin receptor subtypes was evaluated in each tumour. RESULTS: (177)Lu-AMBA identified all GRP-R-expressing tumours, such as prostatic, mammary and renal cell carcinomas as well as gastrointestinal stromal tumours. (177)Lu-AMBA also identified all NMB-expressing tumours, but did not detect BRS-3-expressing tumours or BRS-3-expressing pancreatic islets. GRP-R-expressing peritumoral vessels were heavily labelled with (177)Lu-AMBA. In contrast to the strongly GRP-R-positive mouse pancreas, the human pancreas was not labelled with (177)Lu-AMBA unless chronic pancreatitis was diagnosed. In general, the sensitivity was slightly better with (177)Lu-AMBA than with the conventional bombesin radioligands. CONCLUSION: The present in vitro study suggests that (177)Lu-AMBA may be a very useful in vivo targeting agent for GRP-R-expressing tumours, NMB-R-expressing tumours and GRP-R-expressing neoangiogenic vessels.
PURPOSE: To investigate the in vitro binding properties of a novel radiolabelled bombesin analogue, (177)Lu-AMBA, in human neoplastic and non-neoplastic tissues selected for their expression of the bombesin receptor subtypes GRP-R, NMB-R and BRS-3. METHODS: In vitro receptor autoradiography was performed in cancers expressing the various bombesin receptor subtypes. The novel radioligand (177)Lu-AMBA was used and compared with established bombesin radioligands such as (125)I-Tyr(4)-bombesin and (125)I-[D-Tyr(6),beta-Ala(11),Phe(13),Nle(14)]-bombesin(6-14). In vitro incidence of detection of each of the three bombesin receptor subtypes was evaluated in each tumour. RESULTS: (177)Lu-AMBA identified all GRP-R-expressing tumours, such as prostatic, mammary and renal cell carcinomas as well as gastrointestinal stromal tumours. (177)Lu-AMBA also identified all NMB-expressing tumours, but did not detect BRS-3-expressing tumours or BRS-3-expressing pancreatic islets. GRP-R-expressing peritumoral vessels were heavily labelled with (177)Lu-AMBA. In contrast to the strongly GRP-R-positive mouse pancreas, the human pancreas was not labelled with (177)Lu-AMBA unless chronic pancreatitis was diagnosed. In general, the sensitivity was slightly better with (177)Lu-AMBA than with the conventional bombesin radioligands. CONCLUSION: The present in vitro study suggests that (177)Lu-AMBA may be a very useful in vivo targeting agent for GRP-R-expressing tumours, NMB-R-expressing tumours and GRP-R-expressing neoangiogenic vessels.
Authors: Francesco Scopinaro; Giuseppe De Vincentis; Alexandra D Varvarigou; Cesare Laurenti; Francesco Iori; Silvia Remediani; Stella Chiarini; Salvatore Stella Journal: Eur J Nucl Med Mol Imaging Date: 2003-08-21 Impact factor: 9.236
Authors: C Van de Wiele; F Dumont; R Vanden Broecke; W Oosterlinck; V Cocquyt; R Serreyn; S Peers; J Thornback; G Slegers; R A Dierckx Journal: Eur J Nucl Med Date: 2000-11
Authors: D J Kwekkeboom; W H Bakker; B L Kam; J J M Teunissen; P P M Kooij; W W de Herder; R A Feelders; C H J van Eijck; M de Jong; A Srinivasan; J L Erion; E P Krenning Journal: Eur J Nucl Med Mol Imaging Date: 2003-01-09 Impact factor: 9.236
Authors: Wael R Abd-Elgaliel; Fabio Gallazzi; Jered C Garrison; Tammy L Rold; Gary L Sieckman; Said Daibes Figueroa; Timothy J Hoffman; Susan Z Lever Journal: Bioconjug Chem Date: 2008-09-23 Impact factor: 4.774
Authors: Zhengyuan Zhou; Nilesh K Wagh; Sunny M Ogbomo; Wen Shi; Yinnong Jia; Susan K Brusnahan; Jered C Garrison Journal: J Nucl Med Date: 2013-07-29 Impact factor: 10.057
Authors: Regi Thomas; Jianqing Chen; Martine M Roudier; Robert L Vessella; Laura E Lantry; Adrian D Nunn Journal: Clin Exp Metastasis Date: 2008-10-31 Impact factor: 5.150